2:30 Roundtable Discussion: Discussing Unique PK/PD Properties of Degraders
Time: 10:15 am
day: Day 1 Track B morning
Details:
- Given the notoriously low oral bioavailability of PROTACs, what is your strategy to achieve efficacious concentrations in vivo?
- What is your view regarding PK/PD requirements for long-acting parenteral PROTACs?
- Have you observed any loss of efficacy after repeat treatment and, if so, what could be the potential mechanisms?
